Furthermore, the patients with stage IV GC exhibited significantly lower IFN-λ2/3 levels and higher IFN-α, IFN-β, and IFN-γ levels than the patients with stage I-III GC.
Our findings suggest that MTMR2 is an important promoter in GC invasion and metastasis by inactivating IFNγ/STAT1 signaling and may act as a new prognostic indicator and a potential therapeutic target for GC.
A prominent correlation was observed between the plasma IL-12p70 and IFN-γ levels (r = 0.729, P < .01).Our findings suggest that plasma cytokines and growth factor levels may help predict the development and progression of gastric cancer.
In addition, scFV-3H11 CAR-T cells are able to kill tumor cells accompanied with increased interleukin-2 and interferon-γ secretion <i>in vitro</i>, and reduced the tumor burden in GC cell lines and patient-derived GC cells <i>in vivo</i>.
sLAG3 in PB was poorly expressed and its expression was positively correlated with IL-12 and IFN-γ expression in GC patients. sLAG3 was proved to have a higher diagnostic value than CEA in GC.
IFN-γ and IL-10 levels were significantly higher in early (I/II) and late stage (III/IV) gastric cancer; IL-1β and IL-8 were higher and MCP-1 was lower only in late stage (IV) patients.
Virulent Helicobacter pylori strains that specifically activate signaling in epithelial cells via the innate immune molecule, nucleotide oligomerization domain 1 (NOD1), are more frequently associated with IFN-γ-dependent inflammation and with severe clinical outcomes (i.e., gastric cancer and peptic ulceration).
Comparison of the results from different groups of patients indicated that IFN-gamma gene expression was similar in nonGC dyspeptic patients (NUD and PUD groups; 3.38 +/- 0.57,3.43 +/- 0.41, respectively) whereas, in GC patients, it was significantly higher than others (5.52 +/- 0.59; P < 0.0001).